SEARCH

SEARCH BY CITATION

References

  • 1
    Barnes E. The need for an HCV vaccine. WHO Factsheet 2010. Available at: http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html (last accessed 1 August 2010)..
  • 2
    Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 3
    Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346355.
  • 4
    Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958965.
  • 5
    Zeuzem S, Hultcrantz R, Bourliere M et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40: 993999.
  • 6
    Farnik H, Lange CM, Sarrazin C et al. Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection. Clin Gastroenterol Hepatol 2010; 8: 884890.
  • 7
    Kim JL, Morgenstern KA, Lin C et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996; 87: 343355.
  • 8
    Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5: 453463.
  • 9
    Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138: 447462.
  • 10
    Wakita T, Pietschmann T, Kato T et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791796.
  • 11
    Lamarre D, Anderson PC, Bailey M et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003; 426: 186189.
  • 12
    Reesink HW, Zeuzem S, Weegink CJ et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006; 131: 9971002.
  • 13
    Sarrazin C, Kieffer TL, Bartels D et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 17671777.
  • 14
    Lin C, Lin K, Luong YP et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem 2004; 279: 1750817514.
  • 15
    Lin C, Kwong AD, Perni RB. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets 2006; 6: 316.
  • 16
    Lin K, Perni RB, Kwong AD et al. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrob Agents Chemother 2006; 50: 18131822.
  • 17
    Forestier N, Reesink HW, Weegink CJ et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007; 46: 640648.
  • 18
    Lawitz E, Rodriguez-Torres M, Muir AJ et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol 2008; 49: 163169.
  • 19
    McHutchison JG, Everson GT, Gordon SC et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 18271838.
  • 20
    Hezode C, Forestier N, Dusheiko G et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 18391850.
  • 21
    Forns X, Marcellin P, Ferenci P et al. On-treatment response-guided therapy with telaprevir q8h or q12h combined with peginterferon alfa-2a or peginterferon alfa-2b and ribavirin in treatment-naive genotype 1 hepatitis C (study C208). J Hepatol 2010; 52: S26.
  • 22
    Benhamou Y, Moussalli J, Ratziu V et al. Activity of telaprevir monotherapy or in combination with peginterferon-alfa-2a and ribavirin in treatment-naive genotype 4 hepatitis-C-patients: final results of study C210. Hepatology 2010; 52: 719A.
  • 23
    Foster GR, Hezode C, Bronowicki JP et al. Activity of telaprevir alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naive genotype 2 and 3 hepatitis-C patients: final results of study C209. J Hepatol 2010; 52: S27.
  • 24
    Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: final results of phase 3 ADVANCE study. Hepatology 2010; 52: 427A.
  • 25
    Sherman KE, Flamm SL, Afdhal NH et al. Telaprevir in combination with peginterferon alfa-2a and ribavirin for 24 or 48 weeks in treatment-naive genotype 1 HCV patients who achieved an extended rapid viral response: final results of phase 3 ILLUMINATE study. Hepatology 2010; 52: 401A.
  • 26
    McHutchison JG, Manns MP, Muir AJ et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 12921303.
  • 27
    Vertex Pharmaceuticals Inc. 65% of people whose prior treatment for hepatitis C was unsuccessful achieved SVR (viral cure) with telaprevir-based therapy in phase 3 REALIZE study. Press Release 2010. Available at: http://investors.vrtx.com/releasedetail.cfm?ReleaseID=505239 (last accessed 18 October 2010)..
  • 28
    Susser S, Forestier N, Vermehren J et al. Decline of detectable resistance mutations within the HCV NS3 protease quasispecies during long-term follow-up after treatment with telaprevir. J Hepatol 2010; 52: S300.
  • 29
    Sarrazin C, Rouzier R, Wagner F et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007; 132: 12701278.
  • 30
    Qiu P, Sanfiorenzo V, Curry S et al. Identification of HCV protease inhibitor resistance mutations by selection pressure-based method. Nucleic Acids Res 2009; 37: e74.
  • 31
    Susser S, Welsch C, Wang Y et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009; 50: 17091718.
  • 32
    Tong X, Bogen S, Chase R et al. Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Res 2008; 77: 177185.
  • 33
    Vermehren J, Susser S, Karey U et al. Clonal analysis of mutations selected in the HCV NS3 protease domain of genotype 1 non-responders sequentially treated with boceprevir (SCH503034) and/or pegylated interferon alfa-2b (PEG-IFN alfa-2b). Hepatology 2009; 50: 1040A.
  • 34
    Kwo PY, Lawitz EJ, McCone J et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705716.
  • 35
    Schiff E, Poordad F, Jacobson I et al. Boceprevir combination therapy in null responders: response dependent on interferon responsiveness. J Hepatol 2008; 48: S46.
  • 36
    Bacon BR, Gordon SC, Lawitz E et al. HCV RESPOND-2 final results: high sustained virologic response among genotype 1 previous non-responders and relapsers to peginterferon/ribavirin when re-treated with boceprevir plus pegintron (peginterferon alfa-2b)/ribavirin. Hepatology 2010; 52: 430A.
  • 37
    Poordad F, McCone J, Bacon BR et al. Boceprevir (BOC) combined with peginterferon alfa-2b/ribavirin (P/R) for treatment-naive patients with hepatitis C virus (HCV) genotype (G) 1: SPRINT-2 final results. Hepatology 2010; 52: 402A.
  • 38
    Detishin V, Haazen W, Robison H et al. Virological response, safety, and pharmacokinetic profile following single- and multiple-dose administration of ACH-0141625 protease inhibitor to healthy volunteers and HCV genotype-1 patients. J Hepatol 2010; 52: S468.
  • 39
    Forestier N, Larrey D, Marcellin P et al. Antiviral activity and safety of ITMN-191 in combination with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C virus (HCV). J Hepatol 2009; 50: S35.
  • 40
    Hotho D, de Bruijne J, O’Farrell AM et al. Accelerated clinical trial design to assess the safety, tolerability and anti-viral activity of PHX1766, a novel HCV NS3/4A protease inhibitor, in healthy volunteers and chronic hepatitis C patients. Hepatology 2009; 50: 1031A.
  • 41
    Pasquinelli C, Eley T, Villegas C et al. Safety, tolerability, pharmacokinetics and antiviral activity following single- and multiple-dose administration of BMS-650032, a novel HCV NS3 inhibitor, in subjects with chronic genotype 1 hcv infection. Hepatology 2009; 50: 411A.
  • 42
    Sulkowski M, Ferenci P, Emanoil C et al. SILEN-C1: early antiviral activity and safety of BI 201335 combined with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype 1 HCV infection. Hepatology 2009; 50: 2A.
  • 43
    Brainard DM, Petry A, van Dyck K et al. Safety and antiviral activity of MK-5172, a novel HCV NS3/4A protease inhibitor with potent activity against known resistance mutants, in genotype 1 and 3 HCV-infected patients. Hepatology 2010; 52: 706A.
  • 44
    Goldwater R, DeMicco MP, Zong J et al. Safety, pharmacokinetics, and antiviral activity of single oral doses of the HCV NS3 protease inhibitor GS 9256. Hepatology 2010; 52: 717A.
  • 45
    Lawitz E, Hill JM, Marbury TC et al. Three-day, dose-ranging study of the HCV NS3 protease inhibitor GS-9451. Hepatology 2010; 52: 714A.
  • 46
    de Bruijne J, Bergmann JF, Reesink HW et al. Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients. Hepatology 2010; 52: 15901599.
  • 47
    Terrault NA, Cooper C, Balart LA et al. Phase II randomised, partially-blind, parallel-group study of oral danoprevir (RG7227) with PegIFNalfa-2a (PEGASYS) plus ribavirin in treatment-naive genotype 1 patients with CHC: results of planned week 12 interim analysis of the ATLAS study. Hepatology 2010; 52: 335A.
  • 48
    Manns MP, Gane EJ, Rodriguez-Torres M et al. Sustained viral response (SVR) rates in genotype 1 treatment-naive patients with chronic hepatitis C (CHC) infection treated with vaniprevir (MK-7009), a NS3/4A protease inhibitor, in combination with pegylated interferon alfa-2a and ribavirin for 28 days. Hepatology 2010; 52: 361A.
  • 49
    Berg T, Dieterich DT, Lalezari JP et al. Virological response and safety of 4 weeks treatment with the protease inhibitor BI 201335 combined with 48 weeks of peginterferon alfa 2a and ribavirin for treatment of HCV GT-1 patients who failed peginterferon/ribavirin. Hepatology 2010; 52: 704A.
  • 50
    Fried MW, Buti M, Dore GJ et al. Efficacy and safety of TMC435 in combination with peginterferon alfa-2a and ribavirin in treatment-naive genotype-1 HCV patients: 24-week interim results from the PILLAR study. Hepatology 2010; 52: 403A.
  • 51
    Reesink HW, van Vliet A, Mühr F et al. Antiviral activity, safety and pharmacokinetics of IDX320, a novel macrocyclic HCV protease inhibitor, in a 3-day proof-of-concept study in patients with chronic hepatitis C. Hepatology 2010; 52: 882A.
  • 52
    Lawitz E, Gaultier F, Poordad F et al. 4-week virologic response and safety of ABT-450 given with low-dose ritonavir (ABT-450/r) in combination with pegylated interferon alpha-2a and ribavirin (SOC) after 3-day monotherapy in genotype 1 (GT1) HCV-infected treatment-naive subjects. Hepatology 2010; 52: 878A.
  • 53
    Lawitz E, Nguyen T, Younes Z et al. Clearance of HCV RNA with valopicitabine (NM283) plus peg-interferon in treatment-naive patients with HCV-1 infection: results at 24 and 48 weeks. J Hepatol 2007; 46: S9.
  • 54
    Pockros PJ, Nelson D, Godofsky E et al. R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology 2008; 48: 385397.
  • 55
    Roberts SK, Cooksley G, Dore GJ et al. Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology 2008; 48: 398406.
  • 56
    Jensen DM, Wedemeyer H, Herring RW et al. High rates of early viral response, promising safety profile and lack of resistance-related breakthrough in HCV GT 1/4 patients treated with RG7128 plus PEGIFN alfa-2a (40 KD)/RBV: planned week 12 interim analysis from the propel study. Hepatology 2010; 52: 360A.
  • 57
    Lalezari JP, O’Riordan W, Poordad F et al. A phase IIa study of IDX184 in combination with pegylated interferon (pegIFN) and ribavirin (RBV) in treatment-naive HCV genotype 1-infected subjects. Hepatology 2010; 52: 337A.
  • 58
    Lawitz E, Lalezari JP, Rodriguez-Torres M et al. High rapid virologic response (RVR) with PSI-7977 qd plus PEG-IFN/RBV in a 28-day phase 2a trial. Hepatology 2010; 52: 706A.
  • 59
    Beaulieu PL. Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections. Curr Opin Investig Drugs 2007; 8: 614634.
  • 60
    Lesburg CA, Cable MB, Ferrari E et al. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol 1999; 6: 937943.
  • 61
    Brainard DM, Anderson MS, Petry A et al. Safety and antiviral activity of NS5B polymerase inhibitor MK-3281 in treatment-naive genotype 1a, 1b and 3 HCV-infected patients. Hepatology 2009; 50: 1026A.
  • 62
    Erhardt A, Deterding K, Benhamou Y et al. Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment. Antivir Ther 2009; 14: 2332.
  • 63
    Larrey DG, Benhamou Y, Lohse AW et al. BI 207127 is a potent HCV RNA polymerase inhibitor during 5 days monotherapy in patients with chronic hepatitis C. Hepatology 2009; 50: 1044A.
  • 64
    Larrey DG, Lohse AW, de Ledinghen V et al. 4 week therapy with the non-nucleoside polymerase inhibitor BI207127 in combination with peginterferon-alfa2a and ribavirin in treatment naive and treatment experienced chronic HCV GT1 patients. J Hepatol 2010; 52: S466.
  • 65
    Jacobson IM, Pockros PJ, Lalezari J et al. Virologic response rates following 4 weeks of filibuvir in combination with pegylated interferon alfa-2a and ribavirin in chronically-infected HCV genotype-1 patients. J Hepatol 2010; 52: S465.
  • 66
    Cooper C, Lawitz EJ, Ghali P et al. Evaluation of VCH-759 monotherapy in hepatitis C infection. J Hepatol 2009; 51: 3946.
  • 67
    Lawitz E, Cooper C, Rodriguez-Torres M et al. Safety, tolerability and antiviral activity of VCH-916, a novel non-nucleoside HCV polymerase inhibitor in patients with chronic HCV genotype-1 infection. J Hepatol 2009; 50: S37.
  • 68
    Rodriguez-Torres M, Lawitz E, Conway B et al. Safety and antiviral activity of the HCV non-nucleoside polymerase inhibitor VX-222 in treatment-naive genotype 1 HCV-infected patients. J Hepatol 2010; 52: S14.
  • 69
    Lawitz E, Rodriguez-Torres M, Rustgi VK et al. Safety and antiviral activity of ANA598 in combination with pegylated interferon alfa-2a plus ribavirin in treatment-naive genotype-1 chronic HCV patients. Hepatology 2010; 52: 334A.
  • 70
    Rodriguez-Torres M, Lawitz E, Cohen D et al. Treatment-naive, HCV genotype 1-infected subjects show significantly greater HCV RNA decreases when treated with 28 days of ABT-333 plus peginterferon and ribavirin compared to peginterferon and ribavirin alone. Hepatology 2009; 50: 5A.
  • 71
    Kneteman NM, Howe AY, Gao T et al. HCV796: a selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus. Hepatology 2009; 49: 745752.
  • 72
    Harris J, Bae A, Sun SC et al. Antiviral response and resistance analysis of treatment-naive HCV infected subjects receiving single and multiple doses of GS-9190. Hepatology 2010; 52: 722A.
  • 73
    de Bruijne J, van de Wetering de Rooij J, van Vliet AA et al. Phase I study in healthy volunteers and patients with IDX375, a novel non-nucleoside HCV polymerase inhibitor. Hepatology 2010; 52: 1219A.
  • 74
    Pol S, Everson GT, Ghalib R et al. Once-daily NS5A inhibitor (BMS-790052) plus peginterferon-alpha-2a and ribavirin produces high rates of extended rapid virologic response in treatment-naive HCV-genotype 1 subjects: phase 2a trial. J Hepatol 2010; 52: S462.
  • 75
    Gane EJ, Foster GR, Cianciara J et al. Antiviral activity, pharmakokinetics, and tolerability of AZD7295, a novel NS5A inhibitor, in a placebo-controlled multiple ascending dose study in HCV genotype 1 and 3 patients. J Hepatol 2010; 52: S464.
  • 76
    Colonno R, Peng E, Bencsik M et al. Identification and characterization of PPI-461, a potent and selective HCV NS5A inhibitor with activity against all HCV genotypes. J Hepatol 2010; 52: S14.
  • 77
    Nettles R, Wang X, Quadri S et al. BMS-824393 is a potent hepatitis C virus NS5A inhibitor with substantial antiviral activity when given as monotherapy in subjects with chronic G1 HCV infection. Hepatology 2010; 52: 1203A.
  • 78
    Gane EJ, Roberts SK, Stedman CA et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376: 14671475.
  • 79
    Zeuzem S, Buggisch P, Agarwal A et al. Dual, triple, and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or PegIFN/RBV for up to 28 days in treatment naive, genotype 1 HCV subjects. Hepatology 2010; 52: 400A.
  • 80
    Zeuzem S, Asselah T, Angus PW et al. Strong antiviral activity and safety of IFN-sparing treatment with the protease inhibitor BI 201335, the HCV polymerase inhibitor BI 207127 and ribavirin in patients with chronic hepatitis C. Hepatology 2010; 52: 876A.
  • 81
    Lok AS, Gardiner DF, Lawitz E et al. Combination therapy with BMS-790052 and BMS-650032 alone or with PEGIFN/RBV results in undetectable HCV RNA through 12 weeks of therapy in HCV genotype 1 null responders. Hepatology 2010; 52: 877A.
  • 82
    Rong L, Dahari H, Ribeiro RM et al. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2010; 2: 30ra32.
  • 83
    Flisiak R, Feinman SV, Jablkowski M et al. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 2009; 49: 14601468.
  • 84
    Horban A, Berak H, Kolakowska-Rzadzka A et al. Sustained virological response after 4-week treatment with debio 025 monotherapy or coadministered with PEG-IFN alpha 2a in HCV genotype 1 and 3 patients. J Hepatol 2010; 52: S294.
  • 85
    Coelmont L, Gallay P, Bobardt M et al. Particular in vitro anti-HCV activities and resistance profile of the cyclophilin inhibitor debio 025. J Hepatol 2009; 50: S36.
  • 86
    Coelmont L, Kaptein S, Paeshuyse J et al. Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob Agents Chemother 2009; 53: 967.
  • 87
    Hopkins S, Heuman D, Gavis E et al. Safety, plasma pharmakokinetics, and anti-viral activity of SCY-635 in adult patients with chronic hepatitis C virus infection. J Hepatol 2009; 50: S36.
  • 88
    Hopkins S, Mosier S, Harris R et al. Resistance selection following 15 days of monotherapy with SCY-635, a non-immunosuppressive cyclophilin inhibitor with potent anti-HCV activity. J Hepatol 2010; 52: S15.
  • 89
    Gazak R, Walterova D, Kren V. Silybin and silymarin—new and emerging applications in medicine. Curr Med Chem 2007; 14: 315338.
  • 90
    Ahmed-Belkacem A, Ahnou N, Barbotte L et al. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology 2010; 138: 11121122.
  • 91
    Wagoner J, Negash A, Kane OJ et al. Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology 2010; 51: 19121921.
  • 92
    Ferenci P, Scherzer TM, Kerschner H et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 2008; 135: 15611567.
  • 93
    Rossignol JF, Elfert A, El Gohary Y et al. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 2009; 136: 856862.
  • 94
    Bacon BR, Shiffman ML, Lim JK et al. Phase 2 randomized, double-blind, placebo-controlled study of nitazoxanide plus peginterferon and ribavirin in HCV genotype 1 naive patients: week 12 sustained virologic response rate. J Hepatol 2010; 52: S463.
  • 95
    Nelson DR, Benhamou Y, Chuang WL et al. Randomized trial of albinterferon alfa-2b for the treatment of patients with chronic hepatitis C virus genotype 2 or 3. Gastroenterology 2010; 139: 12671276.
  • 96
    Zeuzem S, Sulkowski MS, Lawitz EJ et al. Randomized trial of albinterferon alfa-2b for the treatment of patients with chronic hepatitis C virus genotype 1. Gastroenterology 2010; 139: 12571266.
  • 97
    Long WA, Takov D, Tchernev K et al. Q2week controlled-release-interferon-alpha2b+ribavirin reduces flu-like symptoms >50% and provides equivalent efficacy in comparison to weekly pegylated-interferon-alpha2b+ribavirin in treatment-naive-genotype-1-chronic-hepatitis C: results from EMPOWER, a randomized-open-label-12-week-comparison in 133 patients. J Hepatol 2010; 52: S467.
  • 98
    Muir AJ, Shiffman ML, Zaman A et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010; 52: 822832.